Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed), eta | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0038 | 0.5597 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1847 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1847 | 0.5 |
Echinococcus multilocularis | dna polymerase eta | 0.0054 | 0.9701 | 0.9633 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0054 | 0.9701 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 0.9701 | 0.9633 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1847 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1847 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Schistosoma mansoni | DNA polymerase eta | 0.0054 | 0.9701 | 0.9633 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1847 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0038 | 0.5597 | 0.4775 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 1 | 1 |
Echinococcus granulosus | dna polymerase eta | 0.0054 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0054 | 0.9701 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0054 | 0.9701 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0054 | 0.9701 | 0.9633 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1847 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0038 | 0.5597 | 0.4775 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488939] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.